Pre and post-surgical immunotherapy improves survival in head and neck cancer patients

CAD/CAM provides clinical benefits in jaw reconstruction surgery

For patients undergoing jaw reconstruction after surgery for head and neck cancer, computer-aided design and manufacturing (CAD/CAM) techniques can improve some key clinical outcomes, reports a study in Plastic and Reconstructive Surgery.

Pre and post-surgical immunotherapy improves survival in head and neck cancer patients

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washi…

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

RAHWAY, N.J.--(BUSINESS WIRE)--Apr 27, 2025-

GeoVax Reveals Promising Clinical Data for Gedeptin® Cancer Therapy at AACR Conference

Researchers from GeoVax Labs have unveiled promising clinical data for Gedeptin®, a gene-directed enzyme prodrug therapy targeting solid tumors, during the American Association for Cancer Research (AACR) Annual Meeting in Chicago. The Phase 1/2 clinical trial focused on advanced head and neck cancer patients, evaluating the safety and efficacy of repeated treatment cycles. The study enrolled eight heavily pretreated patients who had undergone a …

First Clinical Trials Plenary studies support expansion of immunotherapy to more patients - AACR Annual Meeting News

Immunotherapy has transformed the treatment landscape in a variety of cancer types, and as demonstrated during Sunday’s Advances in Immunotherapy Clinical Trial Plenary at the AACR Annual Meeting 2025, immune-targeting treatments have the potential to help many more patients than they do now, including in place of other approaches. KEYNOTE-689: a new standard of care in head and neck cancer? Ravindra Uppaluri, MD, PhD Chaired by AACR Past Presid…

New Standard of Care in Locally Advanced Head and Neck Cancer?

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally advanced head and neck squamous cell carcinoma.